This article has been updated from a previous version to include comments made by Natera executives during an earnings call.

NEW YORK (GenomeWeb) – Natera reported after the close of the market Tuesday that its fourth quarter revenues grew about 9 percent year over year as the company fell short of Wall Street expectations on both the top and bottom lines.

For the three months ended Dec. 31, 2017, Natera tallied revenues of $53.8 million compared to $49.3 million a year ago. Analysts on average had expected Q4 revenues of $57.1 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.